Lunenburg Lymphoma Biomarker Consortium

The Lunenburg Lymphoma Biomarker Consortium (LLBC) is an international effort to standardize the measurement of biomarkers for diffuse large b-cell lymphoma and to validate these biomarkers’ prognostic relevance using data from large clinical trials performed by cooperative groups throughout the world. Over 800 patients in Canada, England, France, Germany, the Netherlands, and the United States will be included in the analysis. Results are expected to be available in December 2006.